Navigation Links
Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Society's 57th Annual Meeting
Date:1/13/2011

tly less opioids were consumed over the first 24 hours after surgery in the EXPAREL group (p=0.0077);
  • EXPAREL was well tolerated in patients who received postsurgical treatment for pain following bunionectomy; 59.8% of patients treated with EXPAREL experienced an adverse event compared to 67.7% of patients treated with placebo;
  • Most of the adverse events were not considered related to study drug and were mild or moderate in severity.

  • The full poster can be found on the Pacira website at www.pacira.com.  

    In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL had been accepted for filing by the U.S. Food and Drug Administration (FDA). Pacira submitted the EXPAREL NDA in September 2010 for the initial indication of postsurgical analgesia by local administration. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 28, 2011 for the review of the EXPAREL NDA.

    About EXPAREL™EXPAREL is Pacira's proprietary drug candidate consisting of bupivacaine encapsulated in DepoFoam®, both of which are currently used separately in FDA-approved products. Bupivacaine is a well-characterized anesthetic/analgesic that has an established safety profile with more than 20 years of use in the United States. Several Phase 2 and Phase 3 clinical trials have been completed for EXPAREL and demonstrate statistically significant reduction of pain in soft tissue and orthopedic surgery in different surgical models. Clinical data has also demonstrated that EXPAREL provides analgesia for up to 72 hours post-surgery compared with 7 hours or less for bupivacaine. The safety of EXPAREL was evaluated in 10 randomized, double-blind, local administration into the surgical wound clinical studies involving 823 patients; the most common adverse events following EXPAREL administration were nausea, constipation, and vomiting.  

    About PaciraPacira P
    '/>"/>

    SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pacira Pharmaceuticals Announces FDA Acceptance of EXPARELâ„¢ New Drug Application for Pain Management
    2. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    3. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
    4. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
    5. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
    6. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
    7. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
    8. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
    9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
    10. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
    11. Optimer Pharmaceuticals Announces Key Additions to Management Team
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... , Sept. 23, 2014  Medela announced today ... Biomedical Company (ABC), assigning Medela as the exclusive distributor ... known as the Medela Enteral Feeding Pump. Through this ... help NICU parents and healthcare professionals by offering a ... Medela Enteral Feeding Pump is integral to the delivery ...
    (Date:9/23/2014)... Sept. 23, 2014 A case report and ... SynCardia temporary Total Artificial Heart into a patient with ... were reversed, along with other abnormalities. ... the SynCardia Total Artificial Heart to treat a patient ... and video in the Journal of Visualized Experiments show ...
    (Date:9/23/2014)... September 23, 2014 BerGenBio ... company, today announces it has been granted a ... Award from the UK,s Wellcome Trust to develop ... novel cancer target. The Wellcome Trust ... fund especially promising, innovative new therapeutic concepts through ...
    Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3
    ... SYDNEY, Sept. 15 HeartWare International, Inc. (Nasdaq: ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... CEO Doug Godshall is scheduled to make an investor ... on Tuesday, September 21, at 12:30 pm EDT.  The ...
    ... Md., Sept. 15 The U.S. Food and Drug ... recommendations for Valcyte (valganciclovir) oral tablets and solution used ... transplant. The update is intended to prevent drug overdosing ... area, and very low serum creatinine. The revised dosing ...
    Cached Medicine Technology:HeartWare to Present at the UBS 2010 Global Life Sciences Conference 2FDA Issues New Dosing Guide for Children Using Valcyte 2
    (Date:9/23/2014)... If you or a loved one ... treatment may be a challenge. Fortunately, an inventor from ... is designed to improve the experience. , He developed ... having to remove, tear or reposition their clothing. Furthermore, ... their dignity. At the same time, it safeguards their ...
    (Date:9/23/2014)... been shown to be a driving force behind ... develops due to chronic inflammation caused by conditions ... relatively few effective treatment options. Now, scientists at ... for the first time in preclinical studies that ... astrocyte elevated gene-1 (AEG-1) halts the development and ...
    (Date:9/23/2014)... Becker's Hospital Review has published ... Hospitals and Health Systems With Great Orthopedic Programs." ... the list have orthopedic surgery departments, programs or ... reputable sources. Exceptional orthopedic departments include physicians who ... and treat professional athletes. , This is the ...
    (Date:9/23/2014)... the curve of oxygen desaturation" (AUC Desat ) may ... levels during procedures using sedation, according to a study ... AUC Desat provides information not only whether blood ... duration, and rate of episodes of oxygen desaturation. ... of Cincinnati and colleagues reports on the development of ...
    (Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
    Breaking Medicine News(10 mins):Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2
    ... WASHINGTON, Aug. 9 SEIU ... wherever they occur. We are ... been raised concerning SEIU Local ... Union, and will take any ...
    ... fade after first injection, so second shot now recommended , , ... chickenpox was introduced in the United States in 1995, medical ... single injection about the time of a child,s first birthday ... so. They,ve found that the protection from a single immunization ...
    ... Responding to increased concerns about the health hazards ... employed the use of the Mini C-Arm throughout ... week are bringing this advanced technology to their ... patient care, Nighttime Care Centers have introduced the ...
    ... of Miley Cyrus and,the Jonas Brothers will have more ... artists take the stage with other performers at Disney,s,Concert ... programs at City of Hope. It will be held ... Tickets for the concert will,be available Saturday, August 16 ...
    ... PD-Rx Pharmaceuticals,Inc., a publicly held corporation, (Pink Sheets: ... of all of its outstanding Preferred "A",stock., ... Cumulative,Convertible Stock representing One Hundred and Sixty Five ... Inc. The,stock call represents PD-Rx,s position to improve ...
    ... Aug. 8 /PRNewswire/ - IntelliPharmaCeutics is pleased to,provide ... press release to,the Company, include IntelliPharmaCeutics Ltd. and ... been very active with drug development work at ... Toronto, Canada. We,presently have 34 staff employed full-time ...
    Cached Medicine News:Health News:Chickenpox Protection: Get That Booster 2Health News:Chickenpox Protection: Get That Booster 3Health News:Nighttime Care Centers Introduce Mini C-Arm Mobile X-Ray Technology to Anne Arundel County 2Health News:Nighttime Care Centers Introduce Mini C-Arm Mobile X-Ray Technology to Anne Arundel County 3Health News:The Walt Disney Company Is Presenting Miley Cyrus, Jonas Brothers and Demi Lovato in a Special Concert to Benefit City of Hope on September 14 2Health News:The Walt Disney Company Is Presenting Miley Cyrus, Jonas Brothers and Demi Lovato in a Special Concert to Benefit City of Hope on September 14 3Health News:PD-Rx Completes Call for Preferred A Stock 2Health News:IntelliPharmaCeutics Provides Update on Activities 2Health News:IntelliPharmaCeutics Provides Update on Activities 3Health News:IntelliPharmaCeutics Provides Update on Activities 4
    ... for the Humphrey Field Analyzer, SITA ... shows less inter-test variability than Full ... of reproducibility as Full Threshold SWAP. ... with the earlier glaucoma damage detected ...
    ... you can trust its capabilities will ... cataract, and glaucoma therapy in one ... is the optimal system for photocoagulation, ... iridotomy. The push of a button ...
    ... The VISUCAM non-mydriatic ... quality and simplicity of ... big enough to set ... photography, it features a ...
    ... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
    Medicine Products: